In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Rebeca GuerreroInstituto Aragonés de Ciencias de la Salud (IACS Aragón), 50009 Zaragoza, Spain.
Mark StrunkInstituto Aragonés de Ciencias de la Salud (IACS Aragón), 50009 Zaragoza, Spain.
Carlota CalvoDepartments of Pediatric Oncology, Clinical Biochemistry and Pathology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
Yolanda González-IrazabalDepartments of Pediatric Oncology, Clinical Biochemistry and Pathology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
Ramiro ÁlvarezDepartments of Pediatric Oncology, Clinical Biochemistry and Pathology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
Jorge E Gomez-SirventDepartment of Pediatrics, Hospital Universitario Nuestra Señora de Candelaria, 38010 Santa Cruz de Tenerife, Spain.
Ricardo López-AlmarazPediatric Oncology-Hematology Unit, Hospital Universitario Cruces, BioBizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0001-5521-9892 Javier Hernández-LosaDepartment of Pathology, Hospital Universitari Vall d'Hebron (HUVH), Campus Vall d'Hebron, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.ORCID 0000-0003-1526-3201 Santiago Ramón Y CajalDepartment of Pathology, Hospital Universitari Vall d'Hebron (HUVH), Campus Vall d'Hebron, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.ORCID 0000-0002-3867-1390 Rebeca González-PastorInstituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain.ORCID 0000-0002-5630-6645 Pilar Martin-DuqueNanomedicines and Nanotherapies Unit, Department of Development of Medicines and Advanced Therapies, Instituto de Salud Carlos III, 28222 Majadahonda, Spain.ORCID 0000-0003-2890-7846 Funding
Instituto de Salud Carlos III PI24CIII/00046Ministry of Science, Technology, Knowledge and Innovation Project CNS2023-145442RAFER RAFER-IBERCAJA GRANT
6 · The paper itselfAbstract
Adenoviruses have been implicated in childhood cancers, primarily leukemia, yet prior neonatal investigations have rarely examined other pediatric tumor types. This study evaluated whether adenoviral early region (
Indexed as
AdenoviridaeAdenovirus E1A ProteinsAdenoviruses, HumanNeoplasmsChildChild, PreschoolDNA, ViralFemaleHumansInfantInfant, NewbornMalePolymerase Chain ReactionAdenovirus E1A ProteinsDNA, Viraladenoviruscytomegalovirusdried blood spotsearly cancer detectionGuthrie cardsnon-invasive diagnosticspediatric oncologySustainable Development Goal 3viral oncogenesis
Identifiers
PMID42123624
PMCPMC13163417
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390